{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T17:04:08Z","timestamp":1766941448861,"version":"3.30.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06100-4","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:42:01Z","timestamp":1732873321000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study"],"prefix":"10.1007","author":[{"given":"Simona","family":"Bernardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Garuffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Toffoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Di Giusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"6100_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","volume":"88","author":"JV Melo","year":"1996","unstructured":"Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375\u20132384","journal-title":"Blood"},{"key":"6100_CR2","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","volume":"99","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C et al (2014) Distinct characteristics of E13a2 versus E14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 99:1441\u20131447. https:\/\/doi.org\/10.3324\/haematol.2013.096537","journal-title":"Haematologica"},{"key":"6100_CR3","doi-asserted-by":"publisher","first-page":"e2020062","DOI":"10.4084\/MJHID.2020.062","volume":"12","author":"M Molica","year":"2020","unstructured":"Molica M, Abruzzese E, Breccia M (2020) Prognostic significance of transcript-type BCR - ABL1 in chronic myeloid leukemia. Mediterr J Hematol Infect Dis 12:e2020062. https:\/\/doi.org\/10.4084\/MJHID.2020.062","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"6100_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, KanagalShamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM et al (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269\u20131275. https:\/\/doi.org\/10.1182\/blood-2015-10-674242","journal-title":"Blood"},{"key":"6100_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","volume":"94","author":"CM Lucas","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE (2009) Chronic myeloid leukemia patients with the E13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the E14a2 transcript. Haematologica 94:1362\u20131367. https:\/\/doi.org\/10.3324\/haematol.2009.009134","journal-title":"Haematologica"},{"key":"6100_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ajh.24774","volume":"92","author":"F Castagnetti","year":"2017","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S et al (2017) The BCR-ABL1 transcript type influences response and Outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol 92:797\u2013805. https:\/\/doi.org\/10.1002\/ajh.24774","journal-title":"Am J Hematol"},{"key":"6100_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.V126.23.597.597","volume":"126","author":"M Bonifacio","year":"2015","unstructured":"Bonifacio M, Scaffidi L, Binotto G, De Marchi F, Maino E, Calistri E, Bonalumi A, Frison L, Marin L, Medeot M et al (2015) Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the gruppo triveneto LMC. Blood 126:597\u2013597. https:\/\/doi.org\/10.1182\/blood.V126.23.597.597","journal-title":"Blood"},{"key":"6100_CR8","doi-asserted-by":"publisher","unstructured":"D\u2019Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A et al (2019) The E13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 125. https:\/\/doi.org\/10.1002\/cncr.31977","DOI":"10.1002\/cncr.31977"},{"key":"6100_CR9","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","volume":"102","author":"S Claudiani","year":"2017","unstructured":"Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D (2017) E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102:e297\u2013e299. https:\/\/doi.org\/10.3324\/haematol.2017.168740","journal-title":"Haematologica"},{"key":"6100_CR10","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L et al (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol 6:e375\u2013e383. https:\/\/doi.org\/10.1016\/S2352-3026(19)30094-8","journal-title":"Lancet Haematol"},{"key":"6100_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M, International BCR-ABL Study Group (2019) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33:1173\u20131183. https:\/\/doi.org\/10.1038\/s41375-018-0341-4","journal-title":"Leukemia"},{"key":"6100_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","volume":"143","author":"M Pfirrmann","year":"2017","unstructured":"Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A et al (2017) No influence of BCR-ABL1 transcript types E13a2 and E14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol 143:843\u2013850. https:\/\/doi.org\/10.1007\/s00432-016-2321-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"6100_CR13","doi-asserted-by":"publisher","unstructured":"Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D et al Effect of a P210 Multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365:657\u2013662. https:\/\/doi.org\/10.1016\/S0140-6736(05)17945-8","DOI":"10.1016\/S0140-6736(05)17945-8"},{"key":"6100_CR14","doi-asserted-by":"publisher","first-page":"ejh.13238","DOI":"10.1111\/ejh.13238","volume":"103","author":"L Kjaer","year":"2019","unstructured":"Kjaer L, Skov V, Andersen MT, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MH, Hasselbalch H et al (2019) Variant-specific discrepancy when quantitating BCR-ABL1 E13a2 and E14a2 transcripts using the Europe against cancer QPCR assay. Eur J Haematol 103:ejh.13238. https:\/\/doi.org\/10.1111\/ejh.13238","journal-title":"Eur J Haematol"},{"key":"6100_CR15","doi-asserted-by":"publisher","unstructured":"Bernardi S, Bonifacio M, Iurlo A, Zanaglio C, Tiribelli M, Binotto G, Abruzzese, E, Russo D (2019) \u201cVariant\u2010specific discrepancy when quantitating BCR\u2010ABL1 E13a2 and E14a2 transcripts using the Europe against cancer QPCR assay.\u201d Is DPCR the key? Eur J Haematol 103. https:\/\/doi.org\/10.1111\/ejh.13282","DOI":"10.1111\/ejh.13282"},{"key":"6100_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, MachovaPolakova K, Dulucq S et al (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999\u20131003. https:\/\/doi.org\/10.1038\/leu.2015.29","journal-title":"Leukemia"},{"key":"6100_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/S41375-022-01607-Z","volume":"1834","author":"HE White","year":"2022","unstructured":"White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P et al (1834) Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia 2022:36. https:\/\/doi.org\/10.1038\/S41375-022-01607-Z","journal-title":"Leukemia"},{"key":"6100_CR18","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.3390\/jcm9123865","volume":"9","author":"S Soverini","year":"2020","unstructured":"Soverini S, Bernardi S, Galimberti S (2020) Molecular testing in CML between old and new methods: are we at a turning point? J Clin Med 9:3865. https:\/\/doi.org\/10.3390\/jcm9123865","journal-title":"J Clin Med"},{"key":"6100_CR19","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/BLOOD.V130.SUPPL_1.2867.2867","volume":"130","author":"C Fava","year":"2017","unstructured":"Fava C, Bernardi S, Gottardi EM, Daraio F, Giugliano E, Lorenzatti R, Varotto M, Barberio D, Galeotti L, Ceccherini F et al (2017) Standardization of two Dpcr platforms for detection of BCR\/ABL1 - minimal residual disease (MRD) in Ph+ chronic myeloid leukemia (CML). Blood 130:2867\u20132867. https:\/\/doi.org\/10.1182\/BLOOD.V130.SUPPL_1.2867.2867","journal-title":"Blood"},{"key":"6100_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/HON.2650","volume":"37","author":"G Colafigli","year":"2019","unstructured":"Colafigli G, Scalzulli E, Porrazzo M, Diverio D, Loglisci MG, Latagliata R, Guarini A, Fo\u00e0 R, Breccia M (2019) Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. Hematol Oncol 37:652\u2013654. https:\/\/doi.org\/10.1002\/HON.2650","journal-title":"Hematol Oncol"},{"key":"6100_CR21","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V et al (2019) Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res 25:6606\u20136613. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3373","journal-title":"Clin Cancer Res"},{"key":"6100_CR22","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/cancers15164112","volume":"15","author":"E Abruzzese","year":"2023","unstructured":"Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, Pacelli P, Re F, Cavalleri A, Farina M et al (2023) Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-QPCR, d-PCR and CD26+ stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers (Basel) 15:4112. https:\/\/doi.org\/10.3390\/cancers15164112","journal-title":"Cancers (Basel)"},{"key":"6100_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000510440","author":"C Zanaglio","year":"2020","unstructured":"Zanaglio C, Bernardi S, Gandolfi L, Farina M, Re F, Polverelli N, Zollner T, Turra A, Morello E, Malagola M et al (2020) RT-QPCR versus digital PCR: how do they impact differently on clinical management of chronic myeloid leukemia patients? Case Rep Oncol. https:\/\/doi.org\/10.1159\/000510440","journal-title":"Case Rep Oncol"},{"key":"6100_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.HS9.0000843520.97381.7b","volume":"6","author":"C Kockerols","year":"2022","unstructured":"Kockerols C, Dulucq S, Bernardi S, Farina M, Civettini I, Colafigli G, Mori S, Valk P, Mahon F-X, Gambacorti-Passerini C et al (2022) S157: BCR::ABL1 digital PCR identifies chronic phase CML patients suitable for an early TKI discontinuation attempt: a patient-level meta-analysis. Hemasphere 6:58\u201359. https:\/\/doi.org\/10.1097\/01.HS9.0000843520.97381.7b","journal-title":"Hemasphere"},{"key":"6100_CR25","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/CAM4.2087","volume":"8","author":"S Bernardi","year":"2019","unstructured":"Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D\u2019Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E et al (2019) Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med 8:2041\u20132055. https:\/\/doi.org\/10.1002\/CAM4.2087","journal-title":"Cancer Med"},{"key":"6100_CR26","doi-asserted-by":"publisher","unstructured":"Izzo B, Gottardi EM, Errichiello S, Daraio F, Barat\u00e8 C, Galimberti S (2019) Monitoring chronic myeloid leukemia: how molecular tools may drive therapeutic approaches. Front Oncol 9. https:\/\/doi.org\/10.3389\/fonc.2019.00833","DOI":"10.3389\/fonc.2019.00833"},{"key":"6100_CR27","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2018-05-848630","volume":"132","author":"N Shanmuganathan","year":"2018","unstructured":"Shanmuganathan N, Hughes TP (2018) Molecular monitoring in CML: how deep? How often? How should it influence therapy? Blood 132:2125\u20132133. https:\/\/doi.org\/10.1182\/blood-2018-05-848630","journal-title":"Blood"},{"key":"6100_CR28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J et al (2018) Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16:1108\u20131135. https:\/\/doi.org\/10.6004\/jnccn.2018.0071","journal-title":"J Natl Compr Canc Netw"},{"key":"6100_CR29","doi-asserted-by":"publisher","unstructured":"Bernardi S, Ruggieri G, Malagola M, Cancelli V, Cattina F, Polverelli N, Zanaglio C, Perucca S, Re F, Montanelli A et al (2017) Digital PCR (Dpcr) a step forward to detection and quantification of minimal residual disease (MRD) in Ph+\/BCR-ABL1 chronic myeloid leukemia (CML). J Mol Biomark Diagn 08. https:\/\/doi.org\/10.4172\/2155-9929.1000330","DOI":"10.4172\/2155-9929.1000330"},{"key":"6100_CR30","doi-asserted-by":"publisher","unstructured":"Spiess B, Rinaldetti S, Naumann N, Galuschek N, Kossak-Roth U, Wuchter P, Tarnopolscaia I, Rose D, Voskanyan A, Fabarius A et al (2019) Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. 14:e0214305. https:\/\/doi.org\/10.1371\/journal.pone.0214305","DOI":"10.1371\/journal.pone.0214305"},{"key":"6100_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.27359","author":"C Kockerols","year":"2024","unstructured":"Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, Atallah E, Mauro MJ, Radich JP, Bernardi S, Russo D et al (2024) BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis. Am J Hematol. https:\/\/doi.org\/10.1002\/AJH.27359","journal-title":"Am J Hematol"},{"key":"6100_CR32","doi-asserted-by":"publisher","first-page":"204062072312056","DOI":"10.1177\/20406207231205637","volume":"14","author":"H Park","year":"2023","unstructured":"Park H, Kim H-J, Sohn S-K, Baik Y, Kim D, Lee S-Y, Kong JH, Kim H, Shin D-Y, Ahn J-S et al (2023) Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor. Ther Adv Hematol 14:20406207231205636. https:\/\/doi.org\/10.1177\/20406207231205637","journal-title":"Ther Adv Hematol"},{"key":"6100_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hemonc.2020.08.003","volume":"15","author":"M Nachi","year":"2022","unstructured":"Nachi M, Kihel I, Entasoltane B, Brahimi M, Yafour N, Guella D, Abed A, Bekadja MA (2022) Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 15:58\u201362. https:\/\/doi.org\/10.1016\/j.hemonc.2020.08.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"6100_CR34","doi-asserted-by":"publisher","first-page":"106512","DOI":"10.1016\/j.leukres.2021.106512","volume":"101","author":"OK Ghalesardi","year":"2021","unstructured":"Ghalesardi OK, Khosravi A, Azizi E, Ahmadi SE, Hajifathali A, Bonakchi H, Shahidi M (2021) The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: a systematic review and meta-analysis. Leuk Res 101:106512. https:\/\/doi.org\/10.1016\/j.leukres.2021.106512","journal-title":"Leuk Res"},{"key":"6100_CR35","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1002\/ajh.24916","volume":"92","author":"M Breccia","year":"2017","unstructured":"Breccia M, Colafigli G, Molica M, Scalzulli E, Diverio D, Latagliata R, Guarini A, Fo\u00e0 R (2017) Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. Am J Hematol 92:E668\u2013E670. https:\/\/doi.org\/10.1002\/ajh.24916","journal-title":"Am J Hematol"},{"key":"6100_CR36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"6100_CR37","doi-asserted-by":"publisher","unstructured":"Marc\u00e9 S, M\u00e9ndez A, Xicoy B, Estrada N, Cabez\u00f3n M, Sturla AL, Garc\u00eda MR, Angona A, Amat P, Escribano Serrat S et al (2024) E14a2 transcript favors treatment-free remission in chronic myeloid leukemia when associated with longer treatment with tyrosine kinase inhibitors and sustained deep molecular response. J Clin Med 13. https:\/\/doi.org\/10.3390\/jcm13030779","DOI":"10.3390\/jcm13030779"},{"key":"6100_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01025-7","volume":"14","author":"M Bonifacio","year":"2024","unstructured":"Bonifacio M, Scaffidi L, Miggiano MC, Facchinelli D, Tosoni L, Pezone S, Griguolo D, Ciotti G, Danini M, Bernardelli A et al (2024) A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements. Blood Cancer J 14:1\u20134. https:\/\/doi.org\/10.1038\/s41408-024-01025-7","journal-title":"Blood Cancer J"},{"key":"6100_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/DISEASES9020035","volume":"9","author":"C Fava","year":"2021","unstructured":"Fava C, Bernardi S, Gottardi EM, Lorenzatti R, Galeotti L, Ceccherini F, Cordoni F, Daraio F, Giugliano E, Jovanovski A et al (2021) Alignment of Qx100\/Qx200 droplet digital (Bio-Rad) and QuantStudio 3D (Thermofisher) digital PCR for quantification of BCR-ABL1 in Ph+ chronic myeloid leukemia. Diseases 9:35. https:\/\/doi.org\/10.3390\/DISEASES9020035","journal-title":"Diseases"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06100-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T10:02:28Z","timestamp":1732874548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06100-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":39,"alternative-id":["6100"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06100-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the ethical committee of Verona, Milano, Udine, Brescia and Padua in July 2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The studies were conducted in accordance with the Declaration of Helsinki and the enrolled patients gave their written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"NP 3809 clinical trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}